Stay updated with breaking news from Greg Baker. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Humira has enjoyed high-priced U.S. exclusivity for 20 years. Its challengers could save the health care system $9 billion and herald savings from the whole class of drugs called biosimilars.
/PRNewswire/ -- Balance Theory, the leading cybersecurity ecosystem management platform, today welcomes Dan Burns, co-founder and former CEO of Optiv, to the...
In separate but related votes this week, the Bossier City Council and DeSoto Parish Police Jury have said no to term limit elections.
Thousands of patients with autoimmune diseases who rely on Humira, with a list price of $6,600 a month, could get financial relief from new low-cost rivals. So far, the pharmacy benefit managers that control drug prices in America have not delivered on those savings.
Tennessee last year spent $48 million on a single drug, Humira — about $62,000 for each of the 775 patients who were covered by its employee health insurance program and receiving the treatment.